# NewGenIvf Group Limited (NIVF)

> Source: Nexqual · https://nexqual.com/NIVF · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, NewGenIvf Group Limited (NIVF), nexqual.com/NIVF" · informational, not investment advice.

**Price:** USD 1.46 (+22.57% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 1.19 · day 1.18–1.68 · 52w 1.14–22,636.8 · market cap $1.2M · NCM

## Key facts
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $119K; 2 not under a Rule 10b5-1 plan ($119K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $4.4M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -100.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Hrt Financial Lp |  | 64,945 | $51K | 78.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-27 | Hrt Financial Lp |  | 85,317 | $68K | 61% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
3 purchases, $4.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-28…2026-07-27 | Cheung Kong Yiu | Director | 3,722,223 | $4.2M | 1.12 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-02…2026-06-03 | Hrt Financial Lp |  | 34,756 | $32K | 0.92 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-22…2026-05-26 | Hrt Financial Lp |  | 165,534 | $162K | 0.98 | Too little history (no open-market trades in 2023–2025) |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2022-03-14) |
|---|---|---|
| Total return | -100.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -100.0% | -98.2% |
| Volatility (annualized) | 254.6% | 171.1% |
| Max drawdown | -100.0% (Oct 2025→Oct 2026) | -100.0% (Mar 2024→Oct 2026) |

## Peers (Medical Care Facilities)
INNV (InnovAge Holding Corp.) USD 9.55 +0.32% · USPH (U.S. Physical Therapy, Inc.) USD 88.53 -0.23% · NUTX (Nutex Health Inc.) USD 209.59 +1.70% · PNTG (The Pennant Group, Inc.) USD 41.88 -0.83% · AGL (agilon health, inc.) USD 89.71 -0.64% · CMPS (COMPASS Pathways Plc - American) USD 11.18 -3.87%

## More
Full page: https://nexqual.com/NIVF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in NIVF's own 20-F filed 2026-03-31 (https://www.sec.gov/Archives/edgar/data/1981662/000121390026037687/ea0283766-20f_newgenivf.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | BNW Real Estate Development | "Khaimah, UAE, is conducted through a joint venture with BNW Real Estate Development LLC ("BNW"), on whom we are heavily reliant" |
| Partner | SAXA | "announced the signing of an service agreement with SAXA to act as the worldwide agent for the tokenization of an initial US$100 million" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | $1365.12 | $27475.21 | -95.0% | $65.1M | 1 |
| Next fiscal year (ends 2027-12-31) | $2689.92 | $109728.03 | -97.5% | $180.4M | 1 |